



Alpine Immune Sciences to Present at 2019 Webbush PacGrow Healthcare Conference

August 1, 2019

SEATTLE--(BUSINESS WIRE)--Aug. 1, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the 2019 Webbush Securities PacGrow Healthcare Conference on Tuesday, August 13, 2019 at 8:00 a.m. Eastern Time in New York, NY.

A live webcast of the presentation will be available online in the investor relations section of the company's website at <https://ir.alpineimmunesciences.com/events>. A replay of the presentation will be available on the company website for 90 days following the webcast.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of functional immune therapeutics. Alpine is employing directed evolution to create potentially powerful multifunctional immunotherapies to improve patients' lives. Alpine has two lead programs. The first, ALPN-101 for autoimmune/inflammatory diseases, is a dual ICOS/CD28 antagonist, engineered to reduce pathogenic immune responses. ALPN-101 is currently enrolling a Phase I healthy volunteer trial. The second, ALPN-202 for cancer, is a conditional CD28 costimulator and dual checkpoint inhibitor. Alpine is backed by world-class research and development capabilities, a highly-productive scientific platform, and a proven management team. For more information, visit www.alpineimmunesciences.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190801005454/en/>

Source: Alpine Immune Sciences, Inc.

Investor Relations:

Pure Communications
Courtney Dugan, 212-257-6723
cdugan@purecommunications.com

Media Relations:

Pure Communications
Sheryl Seapy, 213-262-9390
sseapy@w2ogroup.com